Sickle cell disease (SCD) pain associates with cold temperature and touch. Patients and murine models with SCD have baseline thermal and mechanical pain. In SCD mice, the baseline hypersensitivity is exacerbated by experimental vaso-occlusive crises. We hypothesized that patients with SCD will similarly experience increased hypersensitivity to thermal and mechanical stimuli during acute painful events compared with baseline health. We conducted a prospective study of 24 patients with SCD aged 7 to 19 years. Patients underwent quantitative sensory testing to thermal (cold/heat) and mechanical stimuli on the thenar eminence of the nondominant hand (glabrous skin) and the lateral dorsum of the foot (hairy skin) during baseline health and within 48 hours of hospitalization for acute pain. Primary outcomes were changes in: (1) cold pain threshold (˚C), (2) heat pain threshold (˚C), and (3) mechanical pain threshold (g). Median age was 10.5 (interquartile range [IQR] 9-14.8) years, 67% were females, and 92% were on hydroxyurea. Patients with SCD had increased cold pain sensitivity in the hand during hospitalization compared with baseline (25.2˚C .5˚C] vs 21.3˚C .2˚C]; P 5 0.011) and increased mechanical pain sensitivity in the foot during hospitalization (0.32 g [IQR 0.09-1.1 g] vs 1.7 g [IQR 0.4-8.3 g]; P 5 0.003). There were no differences in heat pain sensitivity. The increased cold (P 5 0.02) and mechanical (P 5 0.0016) pain sensitivity during hospitalization persisted after adjusting for age, sex, hydroxyurea use, opioid consumption, and numeric pain score. Thus, cold and mechanical pain is significantly worse during an acute SCD painful event as compared to baseline health in patients with SCD.
Introduction
Severe, debilitating pain is the most common complication of sickle cell disease (SCD), an inherited hemoglobinopathy affecting ;100,000 people in the United States and over 3 million worldwide. 15, 70 Epidemiological studies reveal that SCD pain frequency and intensity in adults are associated with cold temperatures, increased wind speed, increased barometric pressure, and skin touch. 66, 73, 82 Furthermore, heightened sensitivity to cold temperatures is also a major complaint of patients with SCD and can be a pain trigger. 2, 45, 72, 75, 83 The biological causes of these associations are not yet known. Sickle cell disease pain has clinical features of neuropathic pain, as adolescents and adults with SCD describe their pain as "cold," "hot," and "shooting," and approximately 40% score positive on neuropathic pain screening questionnaires. 11, 34, 93 The precipitating environmental factors and the array of pain descriptors suggest that patients with SCD have hypersensitivity to evoked tactile stimuli, a characteristic of several pain types including neuropathic pain, inflammatory pain, peripheral neuropathies, and centralized pain disorders. 6, 46, 94, 97 Patients with SCD in baseline health have evidence of nervous system sensitization. Compared to race-matched healthy controls, adolescents and adults with SCD during their baseline state of health have hypersensitivity to cold and heat stimuli assessed using quantitative sensory testing (QST). [12] [13] [14] Quantitative sensory testing is a psychophysical testing modality used to interrogate human pain processing through the application of thermal (cold and heat) and mechanical stimuli. These data in adolescents and adults are corroborated by similar findings in SCD murine models where mice display marked behavioral hypersensitivity to mechanical (tactile), cold, and heat stimuli at baseline. 43, 53, 89 The baseline mechanical and cold hypersensitivity in mice is exacerbated by hypoxia-reoxygenation, an experimental method used to induce acute vaso-occlusion. 17, 43 To date, published QST studies in adolescents and adults have assessed patients during baseline health, 14, 19, 34, 68 and in children, after a painful event has occurred. 5 It is not known whether exacerbations in thermal or mechanical pain occur during episodes of acute painful events in patients with SCD. Therefore, the primary objective of this study was to quantify differences in thermal and mechanical pain thresholds in the same child or adolescent with SCD during baseline health and during an acute painful event. We hypothesized that children Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. aged 7 to 19 years with SCD experience increased sensitivity to thermal (cold and heat) and mechanical stimuli during acute painful events as compared to their baseline health.
Methods

Study setting and subjects
A prospective cohort study was conducted between 2014 and 2017. Inclusion criteria were: (1) age 7 to 19 years 61 and (2) diagnosis of SCD (all genotypes). Exclusion criteria were: (1) other chronic disease resulting in pain phenotype or neurological manifestation, (2) history of overt or silent stroke based on known clinical history and available neuroimaging, (3) currently receiving chronic red blood cell transfusions, and (4) pregnancy.
Subject recruitment occurred by 3 mechanisms: (1) preconsenting during routine SCD clinic visits; desire to participate was affirmed if subject was hospitalized for pain, 16 (2) within 48 hours of pain admission, and (3) by phone contact from our previously established database of subjects who consented to be contacted for future pain studies. Patients returned for baseline testing at a time when they had not received opioids for the prior 24 hours (baseline health cohort) and were evaluated when admitted for treatment of an acute painful event (acute pain cohort). All patients were evaluated at both time points. To enhance recruitment and the acquisition of paired data, the order of testing could vary. Thus, some patients had baseline assessments performed first and some had acute pain assessments first. Standard of care for an acute painful event, at the discretion of the treating physician, was given to all patients and included opioids and intravenous fluids. No patients in the study were on chronic opioid therapy at home. The Children's Hospital of Wisconsin Institutional Review Board granted approval for the study. Informed written consent was obtained from the parent or legal guardian, and informed written assent was obtained from the child when age appropriate. Stipends were given for participation, and transportation to the study site was provided for baseline testing. Data were analyzed by coauthors (Pan and Nugent), and all authors had access to the data.
Primary outcomes
The primary outcomes were the change in the following thresholds between the disease states of baseline health and acute pain: (1) cold pain threshold (˚C), (2) heat pain threshold (˚C), and (3) mechanical pain threshold (g). All outcomes were assessed using QST in the same patient during baseline health and during admission for an acute painful event. Per our previous work, baseline state of health was defined as the absence of an acute SCD painful event severe enough to require intravenous opioids within 2 weeks before testing 13, 14 and with no opioids consumed in past 24 hours.
Variables of interest
Age, sex, hydroxyurea use, opioid consumption, and clinical pain score were examined as potential variables of interest that could affect our primary outcome. Opioid consumption was defined in 2 ways: (1) total oral morphine equivalents (OMEs) consumed from presentation in emergency department (ED) through time of QST and (2) total OME in the immediate 1 hour before QST. Older age has been associated with decreased cold and heat pain thresholds (heightened sensitivity), [31] [32] [33] and females have been shown to have higher pain sensitivity than males. 37, 69, 74 Hydroxyurea lessens SCD severity and has been shown to decrease the pain frequency in patients, and therefore, we accounted for hydroxyurea consumption. 24, 90 Opioids have the potential to induce hypersensitivity and pain with chronic administration, and therefore, we accounted for opioid consumption. 26 
Study procedure
Quantitative sensory testing, a psychophysical evaluation of the somatosensory system, 58 was conducted at both study time points (baseline and acute pain). The standard protocol for QST from our previous work was used for this study. 13, 14 Quantitative sensory testing uses the application of physical stimuli (mechanical, heat, and cold) to activate peripheral sensory receptors that subsequently generate pain signals in the pain pathways of the central nervous system (CNS). Quantitative sensory testing can evaluate sensory loss (hyposensitivity) or sensory gain (hypersensitivity) to the applied stimuli. 3, 4 Quantitative sensory testing has been used in children and adults with SCD, 5, 14, 19, 34, 68 a variety of pain conditions such as migraine and headaches, recurrent abdominal pain, rheumatoid pain, 44, 98, 99 and is often used as an outcome in pain clinical trials. 18, 84, 85 Quantitative sensory testing was conducted by 1 of 2 research personnel for the duration of the study. To minimize experimenter bias, the principal investigator did not conduct testing. The site of QST included the thenar eminence (glabrous skin) of the nondominant hand and the lateral dorsum (hairy skin) of the foot; both hand and foot sites were randomized to right/left using a table of random numbers. These testing sites were chosen to be consistent with our previous work and have been used as reference sites in other QST studies. 13, 14, 61 Room temperature was kept constant between 68 and 72˚C, and subjects acclimated to this temperature for 10 to 15 minutes before testing began. Scripted instructions were read to each subject to ensure the testing methodology was standardized. Quantitative sensory testing was completed in the following order: (1) mechanical pain threshold, (2) cold pain threshold, and (3) heat pain threshold. This testing order was chosen because cold/heat pain thresholds tested before mechanical pain thresholds could influence the outcome of mechanical thresholds. 42 Data support that the conduct of QST in this manner is reproducible. 42, 67 The primary outcomes were: (1) cold pain threshold (median of 3 measures), (2) heat pain threshold (median of 3 measures), and (3) mechanical pain threshold (median of 5 measures). The thermal and mechanical thresholds were determined using the "method of limits." 61 
Thermal (cold and heat) testing
Cold and heat stimulation was performed with a Thermal Sensory Analyzer (TSA-II; Medoc, Ramat Yishai, Israel), 60 an FDAapproved computer-assisted QST device. This device was used in our previous SCD work and has been used in QST studies conducted by many other groups in other childhood and adult diseases (ie, chronic regional pain syndrome, migraines, juvenile rheumatoid arthritis, and normal healthy controls). 44, 61, 80, 99 This device delivers cold or warm stimuli through a computer-driven thermode attached to the skin. The baseline temperature was 32˚C (average normal skin temperature in patients), and the stimulus range was 0 to 50˚C. Cold and heat pain thresholds were determined using the "method of limits" where participants were directed to push a button when the sensation of pain was perceived. 61 These thresholds were chosen based on murine studies and other previous QST studies in humans.
61,99
Cold and heat pain thresholds
The probe temperature decreased/increased linearly from baseline temperature (32˚C) at 1.5˚C/second. When the stimulus was painful, a button was pressed, and this was defined as the cold pain or heat pain threshold. The temperature change was then halted, and the thermode temperature was reset to baseline at a rate of 10˚C/second. This procedure was repeated 3 times with an interstimulus interval of 10 seconds. The final cold or heat pain threshold was determined by calculating the median of the 3 threshold temperatures (˚C).
9,61,76,80
Mechanical testing
Mechanical testing was performed using a standardized set of graded von Frey monofilaments that have an applied force on bending that ranges from 0.026 to 110 g. 50 Similar monofilaments have been used in our previous work and other QST studies.
9,13,14,50
Mechanical pain threshold
A subject's hand and foot were placed behind a screen, so he/ she could not see the filament applied to the skin. Starting with the lowest intensity, von Frey filaments were applied with a 1-to 2-second contact time. The "method of limits" 61 was used, where the subject was asked to reply "yes" if the stimulus was "painful." Once this threshold was identified, the operator started again with the lowest von Frey monofilament to assess another threshold. Five threshold determinations (subject answered "yes") were done, and the final threshold was the median of the varying forces (g) of these 5 series. 
Assessment of sedation and pain level
Pain scores were assessed at both testing time points (baseline and acute pain) using the Numeric Rating Scale. 86 To ensure that the patient was able to complete the testing protocol during inpatient admission, sedation scores were obtained before testing. The Pasero Opioid-induced Sedation Scale 65 was used (S 5 sleep, easy to arouse, 1 5 awake and alert, 2 5 slightly drowsy, easily aroused, 3 5 frequently drowsy, arousable, drifts off to sleep during conversation, and 4 5 somnolent, minimal or no response to physical stimulation). If the sedation score was greater than 2 and the subject could not give a pain score, testing was not performed, and the subject's sedation level and pain score were reassessed every 2 hours until the sedation score was 2 or less.
Collection of clinical data
To characterize the study population, age, sex, hydroxyurea use, hemoglobin genotype, and baseline laboratory data (hemoglobin, reticulocyte count, white blood cell count, and hemoglobin F) were collected. Total OMEs 77 consumed in the ED and inpatient unit from arrival until completion of inpatient QST were collected (ie, opioid consumption). All data were extracted from the medical record. Patients completed a questionnaire that elicited responses to weather-related pain triggers and included the following questions: (1) "Do temperature changes from warm to cold trigger your pain?" and (2) "Do temperature changes from cold to warm trigger your pain?"
Data analysis
Patients' characteristics were summarized as median with interquartile range (IQR) for continuous data and n (%) for categorical data. Either appropriate transformations were used to meet parametric assumptions, or a nonparametric method was used. Medians of outcomes were compared between baseline health and acute painful events using the Wilcoxon signed-rank test because the data were nonnormally distributed. In addition, repeated-measures analysis was performed with an unstructured within-subject variancecovariance matrix. The impact of testing order (baseline before acute pain vs acute pain before baseline) on thresholds was investigated by including an order in the model. The impact of genotype (HbSS/HbSO-Arab [most severe] and HbSC/ HbSB 1 -thal [least severe]) was examined similarly. Age, sex, hydroxyurea use, opioid consumption, and numeric pain score at the time of testing were included as covariates. Opioid consumption was defined in 2 ways: (1) total opioids consumed from ED arrival to QST and (2) total opioids consumed in the 1 hour before QST. Log-or squaretransformed data were used to ensure fit. A McNemar exact test was used to determine whether there was a proportional difference in responses to questions regarding weather pain triggers. A P value of ,0.05, with no correction for multiple testing, was considered significant. SPSS version 24 (IBM Software, Chicago, IL) and SAS 9.4 (SAS Institute, Cary, NC) were used to analyze the data.
Results
Study population
A total of 24 patients with SCD completed QST during baseline health and inpatient admission for an acute painful event. Median age at enrollment was 10.5 (IQR 9.0-14.8) years, 67% were females, and 92% were on hydroxyurea. The remainder of the patient characteristics on study entry is summarized in Table 1 . Table 1 Patients' characteristics at study entry (n 5 24). This finding reflects increased cold pain sensitivity during acute painful events as compared to baseline health. There were no significant changes in cold sensitivity in the foot during an acute painful event compared to baseline health. The SCD genotype had no effect on the outcome (P . 0.39). Furthermore, the order of testing (baseline or acute pain first or second) had no effect on the outcome (P . 0.91).
3.3. Patients with sickle cell disease do not display differences in heat pain sensitivity during acute painful events Figure 2 displays the change in median heat pain thresholds between baseline health and acute painful events in the hand and foot. As displayed, there were no significant changes in the heat pain thresholds between baseline health and acute painful events in either the hand or the foot. The decrease in the mechanical pain thresholds indicates that patients have increased mechanical pain sensitivity during acute painful events as compared to their own baseline health. The SCD genotype had no effect on the outcome (P . 0.99). Furthermore, the order of testing had no effect on the outcome (P . 0.17).
3.5. Age, sex, hydroxyurea use, opioid consumption, and clinical pain score do not impact the change in cold and mechanical pain thresholds between baseline health and acute painful events
We evaluated the impact of age, sex, hydroxyurea use, opioid consumption, and clinical pain score on the pain thresholds that significantly changed between baseline and acute painful events. Specifically, we determined whether these covariates affect the change in cold pain thresholds (hand) and mechanical pain thresholds (foot) between the 2 disease states (baseline and acute pain). Age, sex, hydroxyurea use, opioid consumption, and clinical pain score had no significant impact on the change in cold and mechanical pain outcomes ( Tables 2-5) . Disease state, which represents the change between baseline health and acute painful events, with baseline health as the reference in the model, remained significant for cold and mechanical pain after adjusting for the other covariates. Figure 1 . Differences in cold pain thresholds between baseline health and acute painful events. Boxplots displaying differences in median cold pain thresholds between patients with SCD at baseline health and during acute pain (n 5 24, measured at both time points) analyzed using the Wilcoxon signed-rank test. There was a significant increase in the median cold pain threshold in the hand (ie, pain felt closer to 32˚C) during acute pain as compared to baseline health, reflecting increased cold pain sensitivity during acute pain. There were no measured differences in the foot. Note: open circles represent outliers. SCD, sickle cell disease.
Patients report that environmental temperature changes from warm to cold trigger pain
More patients report that temperature changes from warm to cold trigger their pain (yes: 63%) as compared to temperature changes from cold to warm (yes: 26%) (63% vs 26%; P 5 0.039). These data are consistent with hypersensitivity to cold but not warmth in SCD.
Discussion
Using QST, we report that youth with SCD display enhanced sensitivity to cold and mechanical stimuli during acute painful events as compared to their baseline health. This enhanced sensitivity persisted after controlling for age, sex, hydroxyurea use, opioid consumption, and clinical pain. Our data are strengthened by the paired study design where each patient served as their own control, thereby reducing variability.
Epidemiological studies indicate that higher pain frequency and intensity are associated with colder temperatures. 66, 73, 82 We previously showed that patients with SCD have higher cold pain sensitivity compared with healthy African-American controls during baseline health.
14 Similarly, SCD mice display significantly greater sensitivity to cold stimuli at baseline health compared with age-matched controls, and the cold hypersensitivity worsens with age. 89, 96 Furthermore, the baseline cold hypersensitivity in SCD mice is exacerbated by hypoxia-reoxygenation, an experimental method that induces RBC sickling and vaso-occlusion and that mimics the acute pain state in patients with SCD. 17, 43, 53, 96 Data presented here corroborate murine SCD findings by showing that patients have worse cold pain sensitivity during acute painful events compared with their baseline health. Our findings of increased mechanical sensitivity during acute painful events also corroborate patients' pain descriptions and data from neuropathic pain screening tools that show increased Figure 2 . Differences in heat pain thresholds between baseline health and acute painful events. Boxplots displaying differences in median heat pain thresholds between patients with SCD at baseline health and during acute pain (n 5 24, measured at both time points) analyzed using the Wilcoxon signed-rank test. There were no differences in heat pain sensitivity between the 2 time points in the hand or the foot. SCD, sickle cell disease. Figure 3 . Differences in mechanical pain thresholds between baseline health and acute painful events. Boxplots displaying differences in median mechanical pain thresholds between patients with SCD at baseline health and during acute pain (n 5 24, measured at both time points) analyzed using the Wilcoxon signed-rank test. There was a significant decrease in the mechanical pain threshold in the foot during acute pain as compared to baseline health, reflecting an increase in mechanical pain sensitivity during acute pain. There was also a decrease in mechanical pain thresholds in the hand during acute pain as compared to baseline health that approached (but did not reach) significance in the direction of our hypothesis. Note: open circles and asterisks represent outliers. SCD, sickle cell disease. sensitivity to touch or hyperalgesia during vaso-occlusive events. 11, 34, 93 The murine model of SCD has also shown higher baseline mechanical sensitivity than age-matched controls, 23, 43, 53 and the hypersensitivity is exacerbated in SCD mice during hypoxia-reoxygenation-induced acute crises. 17, 43, 79, 91, 96 Thus, our data present new evidence that patients with SCD may have biologic changes that account for the previously described epidemiological, patient-reported, and animal studies of cold and mechanical hypersensitivity. 62, 73, 82, 92 Enhanced cold and mechanical pain sensitivity during acute painful events could be mediated by peripheral nervous system abnormalities. Using in vivo and ex vivo recordings, peripheral C fibers from SCD mice are shown to have more sensitive cold thresholds. 89, 96 C and Ad fibers from SCD mice also show enhanced responsiveness to mechanical stimuli. 38, 43, 89 Candidate cold channels in sensory neurons include Transient Receptor Potential Melastatin 8 (TRPM8) 7, 47, 59, 88 and Transient Receptor Potential Ankyrin 1 (TRPA1). 48, 87 However, there were no changes in mRNA levels or functional responses to agonists for TRPM8 or TRPA1 in dorsal root ganglion sensory neurons from SCD mice. 96 Other putative cold receptors such as KCNK2, KCNQ2, 1, 55 and TASK-3 potassium channel 57,64 could be explored in SCD. The mechanical sensitization of sensory neurons in SCD mice is mediated in part by Transient Receptor Potential Vanilloid 1 (TRPV1). 43 Recent data suggest that the chemokine (c-c motif) ligand 2 (CCL2) and its receptor CCR2 are upstream of both mechanical and cold hypersensitivity in SCD mice. 79 Furthermore, pharmacologic inhibition of peripheral anandamide hydrolysis decreased mechanical hypersensitivity in SCD 89 through a cannabinoid receptor type 1 (CB1) but not CB2 mechanism. Thus, increasing peripheral endocannabinoids could be a novel SCD pain therapy. Other mechanosensitive ion channels such as Piezo2 27,71 may contribute to enhanced mechanical sensitivity in patients with SCD during acute pain and require investigation. Because increased pain sensitivity during acute painful events in patients closely resembles the exacerbation of mechanical sensitivity after hypoxia in SCD mice, the translational mouse model could be used to determine whether altered peripheral mechanisms might serve as novel therapeutic targets for acute SCD pain.
Central nervous system mechanisms could also mediate the enhanced cold and mechanical pain during hospitalization. Little is known about CNS pain mechanisms in SCD. Descending inhibitory pain mechanisms and cortical processing could be altered in SCD and contribute to exacerbation of cold and mechanical hypersensitivity. Pharmacologic activation of muopioid receptors and inhibition of chemokine receptor-5 (CCR-5) attenuated responses of spinal cord neurons to noxious cold and mechanical stimulation of the skin. 22 Furthermore, spinal cord neurons from SCD mice have greater ongoing spontaneous activity, larger receptive fields, and greater discharge rates to the same force of mechanical stimulation of the skin. 23 Ca 21 / calmodulin-dependent protein kinase II (CaMKIIa) has also been studied in SCD mice. CaMKIIa is expressed in the dorsal horn of the spinal cord and some primary sensory neurons. CaMKIIa, activated by intracellular calcium signaling, is implicated in neuroplasticity and its activation is associated with chronic pain states. 25, 28, 35, 95 CaMKIIa inhibition was shown to improve ongoing spontaneous mechanical pain and transiently reverse evoked mechanical sensitivity in SCD mice. 40 A phase I study of trifluoperazine, a CaMKIIa inhibitor, has shown some analgesic effects for SCD pain with neuropathic features. 63 Alternatively, protein kinase C delta (PKCdelta) is shown to be increased in spinal cord GABAnergic inhibitory neurons of SCD mice, and mechanical hyperalgesia was diminished with PKCdelta inhibition. 41 Functional magnetic resonance imaging shows that SCD mice displaying mechanical hyperalgesia have decreased BOLD changes in the thalamus after hypoxia-reoxygenation. 91 Collectively, these data implicate spinal cord and/or brain involvement in the enhanced mechanical sensitivity associated with SCD pain. Notably, with exception of the functional magnetic resonance imaging study, most experiments were conducted in SCD mice during baseline state, not after hypoxia-reoxygenation. Similar or different mechanisms could contribute to the enhanced mechanical sensitization experienced during acute SCD pain vs baseline sensitization. Thus, our work supports the need for additional investigations after hypoxia-reoxygenation in animal models. Alternatively, vascular changes or effects of ischemia on chronic red blood cell sickling may contribute to pain sensitization. For example, blood vessels are innervated by sensory afferent neurons and cold temperatures could stimulate vasoconstriction, thereby contributing to pain exacerbation. 56, 78 Our current study found no changes in heat pain thresholds between baseline and acute pain. Our previous work compared patients with SCD at baseline to healthy AfricanAmerican controls and showed that patients with SCD experience heat hyperalgesia.
14 It is possible that heat hyperalgesia in patients with SCD is static. Patients use heat for analgesia; thus, lack of increased heat hyperalgesia during acute pain may be consistent with patient experience. Sickle cell disease mice show behavioral evidence of heat hyperalgesia compared with controls during the baseline state. 43, 53 The impact of hypoxia-reoxygenation-induced vaso-occlusion on heat hyperalgesia reveals mixed results. After hypoxia, some data show increased heat hyperalgesia, 17 whereas other data show no change. 43 Patients with SCD experienced cold hypersensitivity in glabrous skin of the hand but not in hairy skin of the foot. There is greater epidermal nerve fiber density in the hands compared with feet, and a recent study indicates that hands are twice as sensitive to thermal stimuli as feet. However, hairy skin is more sensitive than glabrous skin to temperature. 36, 51 The difference may be due to glabrous vs hairy skin. Psychophysical studies show that cold pain intensity rises faster in glabrous compared with hairy skin and spatial summation of cold thresholds is greater in glabrous skin. 29, 30, 39 Perception of gentle and noxious cold temperatures is medicated largely by Ad and C fibers, 8, 20, 21, 54, 81 but a detailed study of cold receptors innervating glabrous vs hairy skin has not been reported. 29 Peripheral factors that may underlie the differences include location, depth or density of noxious cold-responsive receptors, or how close the stimulus is to superficial veins innervated by cold-sensitive nociceptors. 29 Furthermore, cold pain perception is likely a function of both the central and peripheral nervous systems, as well as CNS integration of different thermosensitive afferent populations that respond to the stimulus. 29 Differences between hand and foot mechanical pain thresholds were less pronounced than cold. Mechanical pain sensitivity of the foot significantly increased during acute pain, and a trend toward increased mechanical pain sensitivity in the hand (P 5 0.05) was observed.
Limitations
Limitations to our study exist. Opioids can cause sedation; however, we used the Pasero Opioid-induced Sedation Scale 65 before QST and deferred testing if patients were sedated. Selfcompletion of patient-reported measures during acute pain while receiving opioids has been demonstrated. 10, 49, 52 We cannot definitively determine that threshold changes were independent of opioids. Withholding opioids would be unethical in any SCD acute pain study. We attempted to address this issue by accounting for quantity of opioids received in 2 ways as outlined above. Our data show that the quantity of opioids received had no impact on the magnitude of threshold change between baseline and acute pain, suggesting opioids were not driving threshold changes. Because no published data exist regarding pain thresholds during SCD acute painful events, this is the first step in determining the effect of acute pain on these outcomes. Blinding QST testers as to whether subjects were at baseline or acute pain was not possible. Quantitative sensory testing testers were not blinded to the hypothesis, which could have introduced bias. However, the same tester did not always conduct both baseline and hospitalized assessments on a given subject, which could minimize bias. Furthermore, thermal thresholds were computer-driven and all thresholds were patient-reported (not tester determined), which further decreases bias. Because all thresholds did not show differences between baseline and acute pain, the data further support bias was likely not driving the findings. Finally, interim data analyses were not performed, so QST testers did not know data trends mid-study. The sample size was relatively small; however, the paired study design increases the robustness of our findings. The median interval between testing time points was 15.8 (IQR 5.1-22.1) months. To enhance recruitment and acquisition of paired data, we allowed for a 2-year interval between assessments. We found that age did not impact threshold changes and longitudinal pain threshold data within a patient with SCD are currently absent. This is a focus of our current work and could inform this question. We did not measure pain thresholds at the active pain site for 2 reasons. First, we felt it was unacceptable to do QST at the active pain site. Second, we were interested in generalized vs localized pain sensitivity (ie, active pain site). Testing at the pain site could reflect only the sensitivity of the location affected. Other potential confounders may exist, and the ability to account for these in multivariate analyses may be limited due to sample size.
Conclusions
Patients with SCD experience worse cold and mechanical hypersensitivity during hospitalization for acute painful events, whereas no changes in heat sensitivity. Investigation into the etiology of these cold and mechanical sensitivity changes with a focus on peripheral, ascending, descending, and cortical pain pathways could lead to identification of therapeutic targets that could be modulated for treatment or prevention of SCD pain. in the Pediatric Translational Research Unit at Children's Hospital of Wisconsin. Data were log transformed to ensure fit.
